Results for ER+/PR+ disease were similar to those observed for overall breast cancer (ER+/PR+ OR: 1.81 (0.97–3.40); ER–/PR– OR: 1.42 (0.43–4.64)). This evidence concerns the gene ESR1 and breast cancer.